SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
DURHAM, N.C., March 28, 2018 -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today announced that it will report fourth quarter and year-end 2017 financial results and operational highlights prior to the market open on Monday, April 2, 2018.
About Argos Therapeutics
Argos Therapeutics is an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis® technology platform. Argos' most advanced product candidate, Rocapuldencel-T, is being evaluated in the pivotal ADAPT Phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). Argos is also developing a separate Arcelis®-based product candidate, AGS-004, for the treatment of human immunodeficiency virus (HIV), which is currently being evaluated in an investigator-initiated Phase 2 clinical trial aimed at HIV eradication in adult patients. Funding for the development of AGS-004 has been provided by the National Institutes of Health, the National Institute of Allergy and Infectious Diseases, and the Collaboratory of Research for AIDS Eradication.
Investor Contact:
Richard Katz, MD, MBA
Chief Financial Officer
Argos Therapeutics, Inc.
919-287-6315
[email protected]
Media Contact:
Adam Daley
Berry & Company Public Relations
212.253.8881
[email protected]
